ArticleFrontiers in cardiovascular medicine2025
Predictors of B-line count in hospitalized patients with COVID-19.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: B-lines on lung ultrasound (LUS) are nonspecific signs of increased lung density, which can be secondary to pulmonary congestion, pneumonia, or fibrosis. While its use is recommended in acute heart failure (HF), its value in non-HF populations is less clear. Methods: We prospectively analyzed hospitalized non-ICU patients ≥18 years old with confirmed laboratory diagnoses of COVID-19. We aimed to identify associations between 8-zone LUS findings and clinical, laboratory, and echocardiographic data, and 30-day mortality using trend and regression analyses. Results: Among 270 patients (mean age 69 ± 14 years, 58% male, and 11% with prior HF) the median time from hospital admission to LUS was 4 days [interquartile range (IQR) 2-8]. In total, 263 (97%) had ≥1 B-line [median B-line number 13 (IQR 9-22)], and the median left ventricular ejection fraction (LVEF) was 59 (IQR 54-63). In adjusted models, having more B-lines was associated with higher levels of C-reactive protein, with an incidence rate ratio (IRR) of 16% (95%CI: 8%-24%) per log-unit increase ( Conclusions: Among patients with COVID-19, B-lines on LUS are associated with markers of infectious disease severity and pulmonary hypertension, but not with markers of left-sided HF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.